Related Experiment Video
Updated: Aug 9, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Advancing human metapneumovirus vaccine development through fusion protein stabilization
Ahmad Jawad Sabir1, Ted M Ross2
1Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL, USA.
Abstract:
Human metapneumovirus (hMPV) is a major respiratory pathogen that causes a substantial global disease burden, particularly in infants, older adults, and immunocompromised individuals. Despite more than two decades of research, no licensed vaccines or antiviral therapies are available, underscoring a persistent unmet clinical need. The viral fusion (F) glycoprotein is the leading target for vaccine and immunotherapeutic development due to its essential role in viral entry and its ability to elicit neutralizing antibodies. However, hMPV-F is highly metastable and undergoes conformational transitions from a prefusion (pre-F) state on infectious virions to a more stable postfusion (post-F) conformation. Although neutralizing antibodies can target epitopes in both conformations, the pre-F state is particularly important for eliciting the most potent neutralizing responses and is therefore the preferred immunogen for vaccine and antibody-based therapeutic design. This review summarizes recent structure-guided strategies to stabilize hMPV-F in its pre-F conformation, including proline substitutions, disulfide bond engineering, cavity-filling mutations, and scaffold-based approaches. We also synthesize preclinical immunogenicity data from multiple animal models and discuss implications for rational vaccine design. Collectively, these advances, combined with emerging immunological tools and the clinical success of respiratory syncytial virus (RSV) pre-F vaccines, provide a strong foundation to accelerate the development of effective hMPV vaccines and immunotherapeutics.
Insights
Developing effective vaccines against human metapneumovirus (hMPV) is crucial due to its significant respiratory disease burden. Stabilizing the hMPV fusion (F) glycoprotein in its prefusion conformation is key for eliciting potent neutralizing antibody responses.
Area of Science:
- Virology
- Immunology
- Structural Biology
Background:
- Human metapneumovirus (hMPV) is a significant respiratory pathogen causing global disease, especially in vulnerable populations.
- Current unmet medical need exists due to the lack of licensed hMPV vaccines or antiviral therapies.
- The hMPV fusion (F) glycoprotein is a primary target for therapeutic and vaccine development.
Purpose of the Study:
- To review structure-guided strategies for stabilizing the hMPV F glycoprotein in its prefusion conformation.
- To synthesize preclinical immunogenicity data for hMPV vaccine candidates.
- To discuss implications for rational vaccine and immunotherapeutic design against hMPV.
Main Methods:
- Structure-guided protein engineering techniques to stabilize the prefusion conformation of hMPV F glycoprotein.
- Analysis of various stabilization strategies including proline substitutions, disulfide bonds, cavity filling, and scaffolds.
- Review of preclinical immunogenicity data from animal models.
Main Results:
- Several structure-guided strategies effectively stabilize the hMPV F glycoprotein in the prefusion conformation.
- Preclinical studies demonstrate the immunogenicity of stabilized prefusion F antigens.
- Advances in stabilization techniques and immunogenicity data provide a foundation for vaccine development.
Conclusions:
- Stabilizing the hMPV F glycoprotein in the prefusion state is critical for eliciting potent neutralizing antibodies.
- Recent structure-guided approaches show promise for developing effective hMPV vaccines.
- Leveraging insights from RSV vaccine development can accelerate hMPV therapeutic strategies.
